KR101871184B1 - Anti-inflammatory compositions - Google Patents
Anti-inflammatory compositions Download PDFInfo
- Publication number
- KR101871184B1 KR101871184B1 KR1020170151388A KR20170151388A KR101871184B1 KR 101871184 B1 KR101871184 B1 KR 101871184B1 KR 1020170151388 A KR1020170151388 A KR 1020170151388A KR 20170151388 A KR20170151388 A KR 20170151388A KR 101871184 B1 KR101871184 B1 KR 101871184B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- composition
- dermatitis
- inflammatory
- inflammation
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
The present invention relates to an anti-inflammatory composition exhibiting excellent anti-inflammatory effect by controlling the expression of an inflammatory skin disease-related mediator.
Inflammation is the release of histamine and quinine from external biological causes (bacteria, viruses, parasites), physiological causes (mechanical stimulation, heat, radiation, electricity) It is one of the defensive responses of the living body to prevent damage of the living tissue due to increased blood flow, swelling, immune cell and antibody migration, pain, fever and the like, resulting in increase of vascular permeability and inflammation of macrophages.
Inflammatory skin diseases generally refer to eczematous dermatitis. In the acute phase, eczema (vesicle, small blister), erythema (redness of skin) and edema are seen in the acute phase, while edema and blisters are reduced in the chronic phase, while lichniscation (Such as palms and lines that are normally present on the skin due to hardened skin become more pronounced), scales, changes in skin color, and the like. Examples of such eczematous dermatitis include contact dermatitis, atopic dermatitis, and seborrheic dermatitis.
As described above, the inflammatory response in the skin starts as an action to defend skin damage caused by physical stimulation, chemical substances, bacteria, etc., and various immune cells and inflammation-inducing cytokines are involved. Examples of the cytokine include interleukin, growth factor, chemokine, tumor necrosis factor and interferon. Specific examples of the cytokine include insulin, IGF (insulin growth factor) -I, IGF-II, EGF FGF-2, FGF-3, FGF-4, FGF-5, FGF-6 (fibroblast growth factor) , FGF-7, FGF-8, FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, FGF-15, FGF- -19, VEGF (vascular endothelial cell growth factor) -A, VEGF-B, VEGF-C, VEGF-D, NGF (nerve growth factor), IL (interleukin) IL-14, IL-15, IL-6, IL-7, IL-8, IL-9, IL-10, IL- (Granulocyte macrophage colony stimulating factor), G-CSF (granulocyte colony stimulating factor), M-CSF (macrophage colony stimulating factor), SCF (hepatocyte factor), IL-16, IL-17, IL- , FL (flt-3 ligand), andiopoietin, EPO (erythropoietin), TPO (trombopoetin), OSM (Growth factor), HGF (tumor growth factor), TNF (tumor necrosis factor) -α, TNF-α, and LIF (leukemia inhibitor) (Fas ligand), CD40 ligand, MIP (macrophage inflammatory protein), MCP (monocyte chemoattractant protein), IFN (interferon) ?, IFN ?, IFN ?, GDNF Amidotensin and the like.
Currently, synthetic medicines such as ibuprofen, antihistamines, steroids, cortisone, immunosuppressants, and immunosuppressive agents are used for the prevention and treatment of inflammatory skin diseases, but the therapeutic effect is temporary, simple symptom relief, hypersensitivity reaction, And there is a limit to the fundamental treatment of inflammation. In addition, Patent Literatures 1 to 4 disclose various attempts to develop a cosmetic composition having a anti-inflammatory function using a natural extract. However, due to other reasons such as skin irritation or discoloration, the use amount thereof is limited or the solubility in water is poor It was difficult to achieve practical effects due to limitations in application of actual products.
Therefore, it is urgently required to develop a new anti-inflammatory composition that is safer and more effective in the living body than the existing anti-inflammatory composition.
It is an object of the present invention to provide a composition for anti-inflammation that does not cause skin side effects and effectively inhibits skin inflammation.
Specifically, it is an object of the present invention to provide a composition for anti-inflammation which is excellent in prevention and treatment of inflammatory skin diseases by effectively inhibiting the expression of an inflammatory skin disease-related mediator.
The present invention provides a composition for anti-inflammation comprising a compound of the following formula (I) and a compound of the following formula (II) as an active ingredient.
[Chemical Formula 1]
(2)
[In the above formulas (1) and (2)
R 1 and R 3 are each independently selected from the group consisting of hydrogen, (C 1 -C 30) alkyl, (C 2 -C 30) alkenyl, (C 2 -C 30) alkynyl, (C 1 -C 30) alkoxy or hydroxy ;
R 5 is (C 1 -C 30) alkyl, (C 2 -C 30) alkenyl, (C 2 -C 30) alkynyl, (C 1 -C 30) alkoxy or hydroxy (C 1 -C 30) alkyl;
R 2 and R 4 are each independently
In the composition for anti-inflammation according to an embodiment of the present invention, the compounds of Formulas (1) and (2) specifically include compounds wherein R 1 and R 3 are each independently hydrogen, (C 1 -C 30) Or (C2-C30) alkynyl; Wherein R < 5 > is (C1-C30) alkyl; R 2 and R 4 are each independently
In the composition for anti-inflammation according to an embodiment of the present invention, the compounds represented by Chemical Formulas 1 and 2 may be those wherein R 2 and R 4 are each independently selected from the following structures.
[In the above structure,
R 21 and R 22 are each independently hydrogen or (C 1 -C 7) alkyl]
In the composition for anti-inflammation according to an embodiment of the present invention, the compounds of Formulas (1) and (2) are specifically those wherein R 1 and R 3 are each independently hydrogen or (C 1 -C 10) alkyl; Wherein R < 5 > is (C1-C10) alkyl; R 2 and R 4 are each independently
The composition for anti-inflammation according to one embodiment of the present invention may further comprise at least one inflammation selected from interleukin-1, interleukin-1 ?, interleukin-4, interleukin-8, interleukin-13, interleukin-17, TNF (tumor necrosis factor) Induced cytokine expression. That is, the anti-inflammatory composition can suppress the expression of the above-mentioned inflammation-inducing cytokine and reduce excessive secretion of the inflammation-inducing cytokine, thereby achieving excellent inflammation-inhibiting and anti-inflammatory effects.
The anti-inflammatory composition according to one embodiment of the present invention may contain the compound of Formula 1 and the compound of Formula 2 in a weight ratio of 1: 9 to 9: 1.
In the anti-inflammatory composition according to an embodiment of the present invention, the active ingredient may be contained in an amount of 0.001 to 50% by weight based on the total weight of the composition.
The anti-inflammatory composition according to one embodiment of the present invention may have an effect of improving inflammatory skin diseases. Specifically, the inflammatory skin disease is selected from the group consisting of atopic dermatitis, psoriasis, contact dermatitis, eczematous dermatitis, dermatitis dermatitis, seborrheic dermatitis, herpes dermatitis, squamous cellulitis, scleroderma, gigantospermia, pemphigus, , Dermatomyositis, multiple myositis, inflammatory muscle lesions, leprosy or triceps, and the like.
The anti-inflammatory composition according to one embodiment of the present invention may be a pharmaceutical composition for anti-inflammation which is formulated into lotion, ointment, gel, cream, patch, spray or the like.
The composition for anti-inflammation according to one embodiment of the present invention is a composition for anti-inflammation which is formulated into a soft longevity, a convergent lotion, a nutritional lotion, an eye cream, a nutrition cream, a massage cream, a cleansing cream, a cleansing foam, a cleansing water, a powder, Or may be a cosmetic composition for use.
The present invention provides an inflammation-inducing cytokine inhibitor comprising the compound of Formula 1 and the compound of Formula 2 as an active ingredient.
The anti-inflammatory composition of the present invention inhibits the regulation of inflammation-inducing cytokines, thereby effectively preventing the inflammatory reaction and exhibiting an excellent anti-inflammatory effect against inflammatory skin diseases, especially atopic dermatitis and allergic dermatitis.
In addition, the anti-inflammatory composition of the present invention is not only excellent in stability to skin but also excellent in stability.
FIG. 1 shows the results of confirming the expression level of CAII mRNA according to the treatment of Example 1 and Comparative Examples 1 to 3 in the present invention.
FIG. 2 shows the results obtained by quantifying IL-1 mRNA expression quantities according to the treatment of Example 1 and Comparative Examples 1 to 3 in the present invention.
FIG. 3 shows the results of quantitative analysis of IL-1? MRNA expression quantities according to the treatment of Example 1 and Comparative Examples 1 to 3 in the present invention.
FIG. 4 is a graph showing the quantification of IL-8 protein expression levels according to the treatment of Example 1 and Comparative Examples 1 to 3 in the present invention.
The composition for anti-inflammation according to the present invention will be described below. However, unless otherwise defined in the technical terms and scientific terms used herein, it should be understood by those skilled in the art that, In the following description, well-known functions and constructions that may unnecessarily obscure the essentials of the present invention will not be described.
As used herein, the term "inflammation " refers to a phenomenon that occurs when a cell or tissue is damaged by a certain cause, for the purpose of minimizing the reaction and restoring the damaged site to the original purpose. Which causes pain, swelling, redness, fever, and the like, resulting in dysfunction, dysfunction, and dysfunction. The inflammatory skin diseases caused by inflammation are selected from the group consisting of atopic dermatitis, psoriasis, contact dermatitis, eczematous dermatitis, photodermatitis, seborrheic dermatitis, herpes dermatitis, herpes dermatitis, squamous cell, And may be at least one selected from the group consisting of inflammation, scleroderma, dermatomyositis, multiple myositis, inflammatory muscle lesions, leprosy, and three-point syndromes, and allergic dermatitis such as urticaria, insect allergies, food allergies and drug allergies Belongs.
As used herein, the term " inflammation-inducing cytokine " refers to a continuous increase in expression by an inflammatory response, and inhibition of its expression means relieving inflammation.
The term "application, " as used herein, refers to contacting a composition according to the present invention to the skin of a subject by any suitable method, thereby aiming to absorb the composition into the skin.
As used herein, the term "improvement" refers to any action that improves or alters the inflammatory state by application of the composition according to the present invention.
The term " hydroxyalkyl substituted amide compound " or " amino acid compound " as used herein means a compound of one aspect of the present invention. That is, it may be one of the compounds of the formulas (1) and (2) of the present specification.
As used herein, the terms "alkyl", "alkoxy", and other "alkyl" moieties include both linear and branched forms. The alkyl, alkoxy and hydroxyalkyl according to the present invention have a straight-chain carbon number of 1 to 7 or a straight-chain carbon number, but the carbon number of 8 to 30 is also an aspect of the present invention Of course.
As used herein, the term " alkenyl " refers to straight or branched chain hydrocarbons containing at least one double bond, and the term " alkynyl " Means straight chain or branched hydrocarbon.
As used herein, the term " amino acid group " means an amino acid residue derived from an amino acid molecule. Specifically, the amino acid group means a substituent for forming an amide bond by an amino terminal of an amino acid. For example, the amino acid group is Asp = D = aspartic acid group; Ala = A = alanine group; Arg = R = arginine group; Asn = N = asparagine group; Gly = G = glycine group; Glu = E = Glutamic acid group; Gln = Q = glutamine group; His = H = histidine group; Ile = I = isoleucine group; Leu = L = leucine; Lys = K = lysing group; Met = M = methionine group; Phe = F = phenylalanine group; Pro = P = proline group; Ser = S = serine group; Thr = T = threonine group; Trp = W = tryptophan group; Tyr = Y = tyrosine group; Val = V = valine group; And derivatives thereof, and the like.
The applicant of the present invention has conducted studies on new raw materials having excellent stability against the formulation stability while showing the effect of inhibiting the expression of inflammation-inducing cytokines as mediators of inflammatory skin diseases. As a result, it has been found that compounds capable of effectively inhibiting the expression of inflammation- Respectively. As a part of the research, it was surprisingly found that when compounds having different structural characteristics were simultaneously used while exploring the effects on the compounds, remarkable synergistic effects could be realized compared with the case where these compounds were used as a single component, Completed.
Accordingly, the anti-inflammatory composition according to an embodiment of the present invention comprises two or more compounds having different structural characteristics as an active ingredient. Specifically, the active ingredient is at least one compound And at least one compound selected from compounds represented by the following general formula (2).
[Chemical Formula 1]
(2)
[In the above formulas (1) and (2)
R 1 and R 3 are each independently selected from the group consisting of hydrogen, (C 1 -C 30) alkyl, (C 2 -C 30) alkenyl, (C 2 -C 30) alkynyl, (C 1 -C 30) alkoxy or hydroxy ;
R 5 is (C 1 -C 30) alkyl, (C 2 -C 30) alkenyl, (C 2 -C 30) alkynyl, (C 1 -C 30) alkoxy or hydroxy (C 1 -C 30) alkyl;
R 2 and R 4 are each independently
It has been confirmed that each of the compounds described above exhibits an anti-inflammatory effect, that is, an effect of inhibiting the expression of an inflammation-inducing cytokine even when used as a single component. However, the present invention ultimately provides a compound having two or more compounds having different structural characteristics, Which has remarkably improved anti-inflammatory effect compared with the composition of the present invention. In particular, the anti-inflammatory composition according to the present invention is excellent in inhibiting the expression of interleukin-1, interleukin-1β, interleukin-4, interleukin-8, interleukin-13, interleukin-17 and TNF (tumor necrosis factor) .
Furthermore, the composition for anti-inflammation according to one embodiment of the present invention significantly increases the distribution of T cells (Treg cells) that inhibit the activity of inflammatory cells such as macrophages or neutrophils and effectively suppresses the expression of inflammation, .
T cells are immunoregulatory cells, which play a role not only in priming dendritic cells, but also in inflammatory cells and play an important role in skin tissue remodeling. In addition, since T cells exhibit a lower expression level in lesion sites of atopic dermatitis than normal persons, the anti-inflammatory composition according to the present invention is expected to exert an excellent effect in the prevention and treatment of inflammatory skin diseases such as atopic dermatitis.
Hereinafter, specific embodiments of compounds having different structural characteristics as an active ingredient of the anti-inflammatory composition according to one embodiment of the present invention will be described.
The compounds represented by formulas (1) and (2) may be hydroxyalkyl-substituted amide compounds having an amide bond or may be formulated with amino acid-based compounds.
Specifically, the compound of formula (1) and the compound of formula (2) are specifically those wherein R 1 and R 3 are each independently hydrogen, (C 1 -C 30) alkyl, (C 2 -C 30) alkenyl or (C 2 -C 30) alkynyl; Wherein R < 5 > is (C1-C30) alkyl; R 2 and R 4 are each independently
Specifically, the compound of formula (1) and the compound of formula (2) may be those wherein R 2 and R 4 are each independently selected from the following structures.
[In the above structure,
R 21 and R 22 are each independently hydrogen or (C 1 -C 7) alkyl]
Preferably, the compound of formula (I) and the compound of formula (II) are those wherein R 1 and R 3 are each independently hydrogen or (C 1 -C 10) alkyl; Wherein R < 5 > is (C1-C10) alkyl; R 2 and R 4 are each independently
More preferably, the compound of formula (1) and the compound of formula (2) are hydroxyalkyl substituted amide compounds, wherein R 2 and R 4 are each independently selected from the following structures.
The anti-inflammatory composition according to one embodiment of the present invention may contain the active ingredient mixed with the compound of Formula 1 and the compound of Formula 2 in a weight ratio of 0.01: 99.99 to 99.99: 0.01, preferably 1: 9 To 9: 1 by weight, more preferably from 3: 7 to 7: 3 by weight, based on the weight of the active ingredient, but is not limited thereto.
For example, when the active ingredient mixed at the above-mentioned ratio by weight is used, it is preferable to use an effective amount of at least one selected from the group consisting of interleukin-1, interleukin-1 ?, interleukin-4, interleukin-8, interleukin-13, interleukin-17, TNF (tumor necrosis factor) The expression can be remarkably suppressed.
Also, the active ingredients of the anti-inflammatory composition according to one embodiment of the present invention, that is, the compound of Formula 1 and the compound of Formula 2 are excellent in compatibility with additives such as polyol and have excellent solubility in water or ethanol It is expected that it can be formulated into various modes other than the cosmetic composition or the pharmaceutical composition to be used for a general purpose of suppressing the skin immune response and thus the inflammatory reaction.
Hereinafter, specific embodiments of the anti-inflammatory composition according to one embodiment of the present invention will be described.
The composition for anti-inflammation according to one embodiment of the present invention is not only safe for living body but also can control the expression of inflammatory skin disease-related mediators without causing skin side effects such as skin barrier function abnormality, epidermal hyperplasia and the like.
The composition for anti-inflammation according to one embodiment of the present invention specifically includes an expression of interleukin-1, interleukin-1 beta, interleukin-4, interleukin-8, interleukin-13, interleukin-17, TNF (tumor necrosis factor) Thereby giving an improved anti-inflammatory effect. At this time, the present invention uses a composition for anti-inflammation comprising two or more compounds having different structural characteristics as described above, thereby exhibiting surprisingly enhanced synergistic effect on the above-described effect of suppressing the expression of the inflammation-inducing cytokine .
In addition, the anti-inflammatory composition according to one embodiment of the present invention was found to be highly safe for skin by confirming that it does not show toxicity at a concentration range that does not induce cell proliferation.
That is, the anti-inflammatory composition according to one embodiment of the present invention effectively inhibits the expression of an inflammation-inducing cytokine as an external preparation for skin, thereby exhibiting a remarkably enhanced synergistic effect on the anti-inflammatory effect, as well as a skin barrier function abnormality, It is expected that it can be safely and effectively used as a cosmetic composition, a pharmaceutical composition and the like because it does not cause skin side effects, has excellent safety to the skin, is physically and chemically very stable, and is easy to develop a formulation.
The anti-inflammatory composition according to one embodiment of the present invention may have an effect of improving inflammatory skin diseases. At this time, the anti-inflammatory composition can effectively suppress the immune reaction and the inflammatory reaction induced therefrom by controlling the expression level of the inflammation-inducing cytokine.
Examples of inflammatory skin diseases include atopic dermatitis, psoriasis, contact dermatitis, eczematous dermatitis, dermatitis dermatitis, seborrheic dermatitis, herpes dermatitis, squamous cellulitis, scleroderma, gigantospermia, pemphigus, vesicular epidermolysis, systemic sclerosis, Dermatomyositis, multiple myositis, inflammatory muscle lesions, leprosy or triceps syndrome, and the like.
For example, the anti-inflammatory composition is excellent for improving atopic dermatitis or contact dermatitis.
The anti-inflammatory composition such as a cosmetic composition, a pharmaceutical composition, etc. according to an embodiment of the present invention contains the compound of Chemical Formulas 1 and 2 as an active ingredient and the amount of the active ingredient to be used is not particularly limited, By weight, more preferably 0.01 to 30.0% by weight, based on the total weight of the composition.
For example, the active ingredient may be a mixture of the compound of Formula 1 and the compound of Formula 2 in a weight ratio of 0.01: 99.99 to 99.99: 0.01, preferably 1: 9 to 9: 1, May be mixed in a weight ratio of 3: 7 to 7: 3, but the present invention is not limited thereto.
The composition for anti-inflammation according to an embodiment of the present invention includes a residual amount of water, and may further include additional additives. It goes without saying that they can also be formulated in various forms.
Specifically, the composition for anti-inflammation according to one embodiment of the present invention can be formulated into a cosmetic composition for anti-inflammation such as general emulsification formulations and solubilization formulations by using a known manufacturing method.
For example, the anti-inflammatory cosmetic composition may be a formulation selected from the group consisting of softening agents, convergent lotion, nutritional lotion, eye cream, nutritional cream, massage cream, cleansing cream, cleansing foam, cleansing water, powder, essence, But is not limited thereto.
In addition, the anti-inflammatory cosmetic composition may further include additional additives as required. For example, the additive may be at least one selected from the group consisting of stabilizers, emulsifiers, thickeners, moisturizers, liquid crystal film stabilizers, pH adjusters, antimicrobials, water soluble polymers, encapsulants, sequestering agents, amino acids, organic amines, polymer emulsions, At least one aqueous additive selected from an antioxidant, an antioxidant, a preservative, a perfume, and the like; And one or more oily additives selected from oils, waxes, hydrocarbonaceous oils, higher fatty acid oils, higher alcohols, synthetic ester oils, and silicone oils; And the like.
At this time, each of the additives may be included in an amount of 0.001 to 20% by weight based on the total weight of the composition, specifically 0.01 to 10% by weight and 0.05 to 10% by weight, but is not limited thereto.
Specifically, the composition for anti-inflammation according to one embodiment of the present invention can be formulated into a pharmaceutical composition for anti-inflammation including a pharmaceutically acceptable carrier by using a known manufacturing method.
For example, the anti-inflammatory pharmaceutical composition may be formulated into a formulation selected from the group consisting of lotion, ointment, gel, cream, patch, spray, etc., but is not limited thereto.
In addition, the pharmaceutical composition for anti-inflammation may suitably contain a further pharmaceutically acceptable carrier according to the purpose. As an example, there may be mentioned lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose , Methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil, but is not limited thereto. The carrier may further contain a carrier such as a lubricant, a wetting agent, a sweetener, a flavoring agent, an emulsifying agent, a suspending agent, or a preservative.
At this time, each of the carriers may be included in an amount of 0.001 to 20% by weight based on the total weight of the composition, specifically 0.01 to 10% by weight and 0.05 to 10% by weight, but is not limited thereto.
The present invention also provides an inflammation-inducing cytokine inhibitor comprising the compound of Formula 1 and the compound of Formula 2 as an active ingredient. Herein, the inflammation-inducing cytokine inhibitor inhibits the expression of inflammatory cytokines such as interleukin-1, interleukin-1 beta, interleukin-4, interleukin-8, interleukin-13, interleukin-17 and TNF (tumor necrosis factor) In-vitro test or in-vivo test can be used to measure the effect.
In detail, the inflammation-inducing cytokine inhibitor according to an embodiment of the present invention can be used for inhibiting the expression of an inflammation-inducing cytokine in an in-vitro skin cell experiment. As a non-limiting example, by including in the adult keratinocyte or 3D artificial skin tissue cultured on a medium a mixture of the compound of Formula 1 and the compound of Formula 2 according to the present invention as an active ingredient, Can inhibit or inhibit the expression of cyne. The inhibition of the expression of inflammatory cytokines can be simultaneously applied to the inflammation inducing test substance and can be applied to the test for interaction or antagonism with the inflammation inducing test substance. Inflammatory cytokines whose expression is inhibited or inhibited may be an inflammation-inducing cytokine of interleukin-1, interleukin-1 beta, interleukin-4, interleukin-8, interleukin-13, interleukin-17 or TNF (tumor necrosis factor) have.
Hereinafter, preferred embodiments of the present invention will be described in order to facilitate understanding of the present invention. However, the following examples are provided only for the purpose of easier understanding of the present invention, and the following examples are merely illustrative and not intended to limit the scope of the present invention in any way.
(Example 1)
To determine anti-inflammatory efficacy, the expression levels of inflammatory cytokines (IL-1α, IL-1β, IL-8) in atopic dermatitis skin models were measured. At this time, the artificial skin before treatment means a normal skin model.
We used media containing Poly (I: C), TNF-α, IL4 and IL13 to induce atopic dermatitis in human epidermal keratinocytes (HEKn) sold by GIBCO (Invitrogen cell culture) Manufacture of dermatitis skin model). (1: 1) (wt: wt) weight ratio of N- (2-Hydroxyethyl) octanamide and N- (1,3-dihydroxypropan-2-yl) -2-ethylhexanamide And treated for 24 hours in such a manner that the final concentration was 100 μM at a concentration of 0.1%. Then, mRNA and protein wool were extracted from cultured cells and artificial skin to assess the expression level of each inflammatory cytokine.
The results are shown in the following Table 1 and Figs.
(Example 2)
Using the sample prepared by mixing N- (2-Hydroxyethyl) octanamide and N- (1,3-dihydroxy propan-2-yl) -2-ethylhexanamide in a weight ratio of 9: 1 (wt: wt) And the effect was confirmed by the same method.
(Example 3)
Using the sample prepared by mixing N- (2-hydroxyethyl) octanamide and N- (1,3-dihydroxy propan-2-yl) -2-ethylhexanamide in a weight ratio of 8: 2 (wt: wt) And the effect was confirmed by the same method.
(Example 4)
Using the sample prepared by mixing N- (2-Hydroxyethyl) octanamide and N- (1,3-dihydroxypropan-2-yl) -2-ethylhexanamide in a weight ratio of 7: 3 (wt: wt) And the effect was confirmed by the same method.
(Example 5)
(Wt: wt) weight ratio of N- (2-Hydroxyethyl) octanamide and N- (1,3-dihydroxypropan-2-yl) -2-ethylhexanamide in a weight ratio of 3: And the effect was confirmed by the same method.
(Example 6)
(Wt: wt) weight ratio of N- (2-hydroxyethyl) octanamide and N- (1,3-dihydroxypropan-2-yl) -2-ethylhexanamide in a weight ratio of 2: And the effect was confirmed by the same method.
(Example 7)
(Wt: wt) weight ratio of N- (2-Hydroxyethyl) octanamide and N- (1,3-dihydroxypropan-2-yl) -2-ethylhexanamide in a weight ratio of 1: And the effect was confirmed by the same method.
(Comparative Example 1)
The effect was confirmed in the same manner as in Example 1, except that the active ingredient was not used in Example 1 (negative control group). The results are shown in Table 1 and Figs. 1-4.
(Comparative Example 2)
The effect was confirmed by the same method as in Example 1 using a sample containing N- (2-Hydroxyethyl) octanamide as a single component. The results are shown in Table 1 and Figs. 1-4.
(Comparative Example 3)
(1,3-dihydroxy propan-2-yl) -2-ethylhexanamide was used as a single component, and the effect was confirmed by the same method as in Example 1. The results are shown in Table 1 and Figs. 1-4.
As shown in FIG. 1, in the atopic dermatitis skin model according to the present invention, CAII, which is a cytokine which is increased when atopic dermatitis is induced, was increased in Comparative Example 1 as compared with a normal skin model, And 3, the expression level of CAII in Example 1 was remarkably suppressed.
As shown in FIGS. 2, 3 and 4, according to the present invention, in the atopic dermatitis skin model, the expression levels of interleukin-1, interleukin-1β and interleukin-8 compared to Comparative Examples 2 and 3 were remarkably suppressed Respectively.
As shown in Table 1, according to the present invention, up to 23% (Example 1 vs. Comparative Example 2) of the expression level of CAII compared to Comparative Example 1 or 2, which is one example of using each compound as a single component, The expression level of interleukin-1 was 16% (Example 1 vs. Comparative Example 2), the expression level of interleukin-8 was 19% (Example 1 vs. Comparative Example 2) 1 vs. Comparative Example 2).
As described above, the anti-inflammatory effect according to the present invention, that is, the effect of suppressing the expression of the inflammation-inducing cytokine is remarkable compared to the case where each compound is used as a single component, and surprisingly, .
Accordingly, the anti-inflammatory composition according to the present invention effectively inhibits the expression of the inflammatory skin disease-related mediator, and thus it is expected to be used in various formulations because of its excellent immunity against skin irritation and inflammatory response.
While the present invention has been particularly shown and described with reference to exemplary embodiments thereof, it is to be understood that the technical scope of the present invention is not limited to the disclosed exemplary embodiments. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
Claims (13)
[Chemical Formula 1]
(2)
[In the above formulas (1) and (2)
R < 1 > is hydrogen or (C1-C30) alkyl;
R 3 is hydrogen, (C 1 -C 30) alkyl, (C 2 -C 30) alkenyl or (C 2 -C 30) alkynyl;
R 5 is (C1 ~ C30) alkyl, (C2-C30) alkenyl or (C2-C30) alkynyl;
R 2 and R 4 are each independently
Of the compounds of Formulas 1 and 2 above,
Wherein R 2 and R 4 are each independently selected from the following structures:
[In the above structure,
R 21 and R 22 are each independently hydrogen or (C 1 -C 7) alkyl]
Of the compounds of formulas (1) and (2)
Wherein R 1 and R 3 are each independently hydrogen or (C 1 -C 10) alkyl;
Wherein R < 5 > is (C1-C10) alkyl;
R 2 and R 4 are each independently
The composition may comprise,
Wherein the compound of Formula 1 and the compound of Formula 2 are contained in a weight ratio of 1: 9 to 9: 1.
The above-
0.001 to 50% by weight based on the total weight of the composition.
The composition may comprise,
A pharmaceutical composition for antiinflammation.
The pharmaceutical composition may contain,
Lotion, ointment, gel, cream, patch or spray.
The pharmaceutical composition may contain,
Which is effective for improving inflammatory skin diseases.
The inflammatory skin disease is selected from the group consisting of atopic dermatitis, psoriasis, contact dermatitis, eczematous dermatitis, dermatitis dermatitis, dermatitis dermatitis, herpes dermatitis, herpes zoster dermatitis, squamous cellulitis, scleroderma, gangrenous epidermolysis, , Multiple myositis, inflammatory muscle lesions, leprosy or triceps.
The composition may comprise,
A cosmetic composition for anti-inflammation.
In the cosmetic composition,
A cosmetic composition for anti-inflammation, which is formulated with a softening agent, a softening agent, a convergent lotion, a nutritional lotion, an eye cream, a nutritional cream, a massage cream, a cleansing cream, a cleansing foam, a cleansing water, a powder, an essence or a pack.
[Chemical Formula 1]
(2)
[In the above formulas (1) and (2)
R < 1 > is hydrogen or (C1-C30) alkyl;
R 3 is hydrogen, (C 1 -C 30) alkyl, (C 2 -C 30) alkenyl or (C 2 -C 30) alkynyl;
R 5 is (C1 ~ C30) alkyl, (C2-C30) alkenyl or (C2-C30) alkynyl;
R 2 and R 4 are each independently
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170151388A KR101871184B1 (en) | 2017-11-14 | 2017-11-14 | Anti-inflammatory compositions |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170151388A KR101871184B1 (en) | 2017-11-14 | 2017-11-14 | Anti-inflammatory compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101871184B1 true KR101871184B1 (en) | 2018-06-27 |
Family
ID=62790113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170151388A KR101871184B1 (en) | 2017-11-14 | 2017-11-14 | Anti-inflammatory compositions |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101871184B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102128260B1 (en) * | 2020-03-13 | 2020-06-30 | (주)네오팜 | Cosmetics composition containing amide compound |
-
2017
- 2017-11-14 KR KR1020170151388A patent/KR101871184B1/en active IP Right Grant
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102128260B1 (en) * | 2020-03-13 | 2020-06-30 | (주)네오팜 | Cosmetics composition containing amide compound |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022116295A (en) | Topical compositions and methods for treating inflammatory skin diseases | |
| JP3211027B2 (en) | Topical containing capsaicin | |
| RU2327460C2 (en) | Immunomodulator-containing pharmaceutical formulations | |
| AU2010257466B2 (en) | Epidermal growth factor composition, a process therefor and its application | |
| KR101828241B1 (en) | Composition for anti-inflammatory | |
| ES2371671T3 (en) | USE OF PHENYLBUTYRIC ACID OR SALTS OF THE SAME TO TREAT THE PRURITE. | |
| JPH08500092A (en) | Dermatological composition | |
| WO2020058992A1 (en) | Improved and stable apremilast pharmaceutical compositions | |
| DE10154579A1 (en) | Topical use of cytokines and chemokines for the treatment of viral or mycotic skin diseases or tumors | |
| KR101871184B1 (en) | Anti-inflammatory compositions | |
| TW201605444A (en) | Topical pharmaceutical or cosmetic compositions comprising octenidine dihydrochloride | |
| PL190023B1 (en) | Application of a mixture of diole and alpha-hydroxyacid in treating | |
| KR101911377B1 (en) | Composition for anti-inflammatory | |
| US6964783B1 (en) | Non-solid composition for local application | |
| EP0294914A2 (en) | Nedocromil for the treatment of dermatological disorders | |
| US20040202640A1 (en) | Method for topical treatment of scars with rotein Kinase C inhibitors | |
| US20220142990A1 (en) | External preparation for treating a vascular anomaly | |
| KR20150023570A (en) | Pharmaceutical composition for treating inflammation and pain | |
| KR101828240B1 (en) | Composition for anti-inflammatory | |
| EP0943334A1 (en) | Tortoise oil, turtle oil, compositions containing them, their preparation processes and uses | |
| KR102323657B1 (en) | Composition for anti-inflammatory | |
| JP2020011993A (en) | Skin external application agent | |
| KR20200108297A (en) | Serdulatinib-containing topical dermal pharmaceutical composition and uses thereof | |
| JP7329910B2 (en) | Skin topical composition | |
| JP7406778B1 (en) | External skin preparation containing aniline derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |